

DAFTAR PUSTAKA

1. Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. *World J Gastroenterol.* 2012 Aug;18(29):3790–9.
2. Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. *Gut.* 2014 Apr;63(4):588–97.
3. Simadibrata M, Adiwinata R. Current Issues of Gastroenterology in Indonesia. *Acta Med Indones.* 2017;49(3):270–8.
4. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. *Inflamm Bowel Dis.* 2011 Jan;17(1):179–84.
5. Berding K, Vlckova K, Marx W, Schellekens H, Stanton C, Clarke G, et al. Diet and the Microbiota-Gut-Brain Axis: Sowing the Seeds of Good Mental Health. *Adv Nutr.* 2021 Jul;12(4):1239–85.
6. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. *PeerJ.* 2019;7:e7502.
7. Yu W, Su X, Chen W, Tian X, Zhang K, Guo G, et al. Three types of gut bacteria collaborating to improve Kui Jie'an enema treat DSS-induced colitis in mice. *Biomed Pharmacother.* 2019 May;113:108751.
8. Drago L. Probiotics and Colon Cancer. *Microorganisms.* 2019 Feb;7(3).
9. Aindelis G, Chlichlia K. Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria. *Vaccines (Basel).* 2020 Jun;8(2).
10. Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. *BMC Gastroenterol.* 2019 Jul;19(1):131.
11. Wirawati C. Characteristic and Development of Cow's Milk Dadih as an Alternate of Buffalo's Milk Dadih. *Indonesian Bulletin of Animal and Veterinary Sciences.* 2018;27:95.
12. Usmiati S, Risfaheri. Pengembangan Dadih Sebagai Pangan Fungsional Probiotik Asli Sumatera Barat. *J Litbang Pert.* 2013;32(1):20–9.
13. Fitria N, Sukma A. Microbiota community structure in traditional fermented milk dadih in Indonesia: Insights from high-throughput 16S rRNA gene sequencing. 2017;
14. Mills, Ross, Coffey A. Mills, S., Ross, R.P., & Coffey, A. (2011). Lactic Acid Bacteria: *Lactococcus lactis*. In *Encyclopedia of Dairy Science*, 2nd Edition. Eds: John W. Fuquay, Patrick F. Fox and Paul L.H. McSweeney. Academic Press - Elsevier, London and Oxford, Ukand San Diego. In 2011. p. 132–7.
15. Park B, Kim I, Park J, Zhi Z, Lee H, Kwon O, et al. Probiotic effect of *Lactococcus lactis* subsp. *cremoris* RPG-HL-0136 on intestinal mucosal immunity in mice. *Appl Biol Chem.* 2021;64.

16. Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. *Gastroenterology*. 2015 Oct;149(5):1275-1285.e2.
17. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet*. 2011;43(3):246–252.
18. Heller F, Fromm A, Gitter AH, Mankertz J, Schulzke JD. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. *Mucosal Immunol*. 2008 Nov;1 Suppl 1:S58-61.
19. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. *Gastroenterology*. 2005 Aug;129(2):550–64.
20. Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. *Aliment Pharmacol Ther*. 2011 Jan;33(1):115–26.
21. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. *J Clin Lab Immunol*. 1995;46(3):111–23.
22. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. *J Clin Lab Immunol*. 1995;46(3):111–23.
23. Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol*. 2005 Sep;19 Suppl A:5A-36A.
24. Hrabe JE, Byrn JC, Button AM, Zamba GK, Kapadia MR, Mezhir JJ. A matched case-control study of IBD-associated colorectal cancer: IBD portends worse outcome. *J Surg Oncol*. 2014 Feb;109(2):117–21.
25. Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. *Inflamm Bowel Dis*. 2011 Mar;17(3):802–8.
26. Yuniastuti A. PROBIOTIK (Dalam Perspektif Kesehatan). 2014.
27. Dommels YEM, Kemperman RA, Zebregs YEMP, Draaisma RB, Jol A, Wolvers DAW, et al. Survival of *Lactobacillus reuteri* DSM 17938 and *Lactobacillus rhamnosus* GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. *Appl Environ Microbiol*. 2009 Oct;75(19):6198–204.
28. Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, et al. Anti-inflammatory effects of *Lactococcus lactis* NCDO 2118 during the remission period of chemically induced colitis. *Gut Pathog*. 2014;6:33.
29. Nishitani Y, Tanoue T, Yamada K, Ishida T, Yoshida M, Azuma T, et al. *Lactococcus lactis* subsp. *cremoris* FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. *Int Immunopharmacol*. 2009 Nov;9(12):1444–51.

30. Sharma A. Chapter 4 - Importance of Probiotics in Cancer Prevention and Treatment. In: Buddolla V, editor. *Recent Developments in Applied Microbiology and Biochemistry*. Academic Press; 2019. p. 33–45.
31. Sivamaruthi B, Kesika P, Chaiyasut C. The Role of Probiotics in Colorectal Cancer Management. *Evidence-based Complementary and Alternative Medicine*. 2020;2020.
32. Li C, Lau HCH, Zhang X, Yu J. Mouse Models for Application in Colorectal Cancer: Understanding the Pathogenesis and Relevance to the Human Condition. *Biomedicines*. 2022 Jul;10(7).
33. Parang B, Barrett CW, Williams CS. AOM/DSS Model of Colitis-Associated Cancer. *Methods Mol Biol*. 2016;1422:297–307.
34. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. *Gut*. 2010 Sep;59(9):1192–9.
35. Gileta AF, Fitzpatrick CJ, Chitre AS, St Pierre CL, Joyce E V, Maguire RJ, et al. Genetic characterization of outbred Sprague Dawley rats and utility for genome-wide association studies. *PLoS Genet*. 2022 May;18(5):e1010234.
36. Parker CC, Chen H, Flagel SB, Geurts AM, Richards JB, Robinson TE, et al. Rats are the smart choice: Rationale for a renewed focus on rats in behavioral genetics. *Neuropharmacology*. 2014 Jan;76 Pt B(00):250–8.
37. Adamkova P, Hradicka P, Kupcova Skalnikova H, Cizkova V, Vodicka P, Farkasova Iannaccone S, et al. Dextran Sulphate Sodium Acute Colitis Rat Model: A Suitable Tool for Advancing Our Understanding of Immune and Microbial Mechanisms in the Pathogenesis of Inflammatory Bowel Disease. *Vet Sci*. 2022;9(5).
38. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms*. 2019 Jan;7(1).
39. Stojanov S, Berlec A, Štrukelj B. The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease. *Microorganisms*. 2020 Nov;8(11).
40. Grigor'eva IN. Gallstone Disease, Obesity and the Firmicutes/Bacteroidetes Ratio as a Possible Biomarker of Gut Dysbiosis. *J Pers Med*. 2021;11(1).
41. Huang Y, Shi X, Li Z, Shen Y, Shi X, Wang L, et al. Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder. *Neuropsychiatr Dis Treat*. 2018;14:3329–37.
42. Vaiserman A, Romanenko M, Piven L, Moseiko V, Lushchak O, Kryzhanovska N, et al. Differences in the gut Firmicutes to Bacteroidetes ratio across age groups in healthy Ukrainian population. *BMC Microbiol*. 2020;20(1):221.
43. Zafar H, Saier MHJ. Gut Bacteroides species in health and disease. *Gut Microbes*. 2021;13(1):1–20.
44. Johnson EL, Heaver SL, Walters WA, Ley RE. Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes. *J Mol Med*. 2017;95(1):1–8.

45. Štofilová J, Kvaková M, Kamlárová A, Hijová E, Bertková I, Guľašová Z. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. *Biomedicines*. 2022 Sep;10(9).
46. Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Vol. 8, *Microorganisms*. MDPI AG; 2020. p. 1–16.
47. Pesce M, Seguella L, Del Re A, Lu J, Palenca I, Corpetti C, et al. Next-Generation Probiotics for Inflammatory Bowel Disease. *Int J Mol Sci*. 2022 May;23(10).
48. Rizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: A Common Factor in Human Diseases. Canducci F, editor. *Biomed Res Int*. 2017;2017:9351507.
49. Cevallos SA, Lee JY, Tiffany CR, Byndloss AJ, Johnston L, Byndloss MX, et al. Increased Epithelial Oxygenation Links Colitis to an Expansion of Tumorigenic Bacteria. *mBio*. 2019;10(5):10.1128/mbio.02244-19.
50. Binda C, Lopetuso LR, Rizzatti G, Gibiino G, Cennamo V, Gasbarrini A. Actinobacteria: A relevant minority for the maintenance of gut homeostasis. *Digestive and Liver Disease*. 2018;50(5):421–8.
51. Yu D, Xia Y, Ge L, Tan B, Chen S. Effects of *Lactococcus lactis* on the Intestinal Functions in Weaning Piglets. *Front Nutr*. 2021;8(August):1–10.
52. Ma T, Shen X, Shi X, Sakandar HA, Quan K, Li Y, et al. Targeting gut microbiota and metabolism as the major probiotic mechanism - An evidence-based review. *Trends Food Sci Technol*. 2023;138:178–98.
53. Dhillon P, Singh K. Therapeutic applications of probiotics in ulcerative colitis: An updated review. Vol. 13, *PharmaNutrition*. Elsevier B.V.; 2020.
54. Binda C, Lopetuso LR, Rizzatti G, Gibiino G, Cennamo V, Gasbarrini A. Actinobacteria: A relevant minority for the maintenance of gut homeostasis. Vol. 50, *Digestive and Liver Disease*. Elsevier B.V.; 2018. p. 421–8.
55. Pesce M, Seguella L, Del Re A, Lu J, Palenca I, Corpetti C, et al. Next-Generation Probiotics for Inflammatory Bowel Disease. Vol. 23, *International Journal of Molecular Sciences*. MDPI; 2022.

